Utility of Soluble CD163 in the Clinical Management of Patients With Kawasaki Disease

Objective: Intravenous immunoglobulin (IVIG) therapy is a useful first-line treatment for Kawasaki disease (KD); however, 10–20% of patients fail to respond and require additional IVIG. Soluble CD163 (sCD163) is considered a biomarker for macrophage activation. There are no reports measuring serum s...

Descripción completa

Detalles Bibliográficos
Autores principales: Azuma, Yoshihiro, Suzuki, Yasuo, Okada, Seigo, Matsuguma, Chie, Wakiguchi, Hiroyuki, Ohnishi, Yuji, Furuta, Takashi, Miyake, Akiko, Yasudo, Hiroki, Ichihara, Kiyoshi, Ohga, Shouichi, Hasegawa, Shunji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Pediatrics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7154120/
https://www.ncbi.nlm.nih.gov/pubmed/32318530
http://dx.doi.org/10.3389/fped.2020.00148

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7154120/
https://www.ncbi.nlm.nih.gov/pubmed/32318530
http://dx.doi.org/10.3389/fped.2020.00148

Ejemplares similares